Health
FDA authorizes fingerstick COVID-19 antibody test – Mass Device
Nirmidas Biotech announced this week that it received FDA emergency use authorization (EUA) for its COVID-19 test in point-of-care settings.
Nirmidas Biotech announced this week that it received FDA emergency use authorization (EUA) for its COVID-19 test in point-of-care settings.
Palo Alto, Calif-based Nirmidas Biotech’s MidaSpot rapid COVID-19 antibody combo detection kit uses fingerstick serology testing to detect IgG/IgM antibodies related to the SARS-CoV-2 virus causing COVID-19, according to a news release.
MidaSpot, touted by Nirmidas as the first point-of-care fingerstick COVID-19 test to receive EUA, can now be administered…
-
Noosa News19 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
Noosa News22 hours ago’Lethal new opioids’ prompt Wide Bay pill testing call
-
General18 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News18 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland